Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Jennifer A. Marks
ResearcherPublications, citations & collaboration network
Jennifer A. Marks is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 4 works, 0 citations, an h-index of 0 and an i10-index of 0.
4
Works
0
Citations
0
h-index
0
i10-index
IDs:OpenAlex
How has Jennifer A. Marks's publication output changed over time?
ScholarIQpublication output · 2026
4
2026
What are the most-cited papers on Jennifer A. Marks?
ScholarIQmost cited works
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer
Jennifer A. Marks, Kieran Sweeney, Andrew Elliott, Brinda Gupta, Ari VanderWalde, Sonam Puri, Misty Dawn Shields, Jorge J. Nieva, Heloisa Resende SOARES, Patrick C. Ma, Balázs Halmos, Stephen V. Liu
Lung Cancer. 20260 Citations
Abstract CT281: A phase II trial of ivonescimab for previously treated thymic carcinoma UCLA L-11
Jonathan Boiarsky, Chi-hong Tseng, Zhaohui Arter, Matthew A. Gubens, Chul Kim, Jennifer A. Marks, Surbhi Singhal, Christine Kivork, Larissa Ikenouye, Jonathan W. Goldman
Cancer Research. 20260 Citations
A phase II trial of ivonescimab for previously treated thymic carcinoma: UCLA L-11.
Jonathan Boiarsky, Chi‐Hong Tseng, Zhaohui Arter, Matthew A. Gubens, Chul Kim, Jennifer A. Marks, Surbhi Singhal, Christine Kivork, Larissa Ikenouye, Jonathan W. Goldman
Journal of Clinical Oncology. 20260 CitationsOPEN ACCESS
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology
Jennifer A. Marks, Rohan Maniar, Kavitha Ramchandran, Erica Pietroluongo, Mehmet Altan, Surbhi Singhal, M Aldea, Jonathan W. Goldman, Jonathan W. Reiss, Heather Wakelee, Patrick J. Loehrer, Marina Chiara Garassino, Anja C. Roden, J Remon, Christopher S. Nabel, Chul Kim
S4210211538. 20260 CitationsOPEN ACCESS
Related on ScholarIQ
Harvard University
Institution
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer
Paper
Abstract CT281: A phase II trial of ivonescimab for previously treated thymic carcinoma UCLA L-11
Paper
A phase II trial of ivonescimab for previously treated thymic carcinoma: UCLA L-11.
Paper
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology
Paper
Myasthenia Gravis and Thymoma
Topic